HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs
HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer and other diseases, announced today it has filed two investigational new drug (IND) applications (HF158K1 and HFK2) with China’s National Medical Products Administration for immunoliposomes carrying different cancer killing payloads. The planned clinical study will evaluate the two drugs’ safety and pharmacokinetics as well as their combined therapeutic effects in solid tumor patients refractory to prior treatments.
Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases
HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer and other diseases, announced today publication of two scientific journal articles revealing the importance of LNP structure design on the in vivo behavior of LNPs in delivering RNA molecules.
HighField Biopharmaceuticals Granted Clearance of IND in China for Clinical Trial of its Unique TRAFsomeTM T Cell Engager (HF50) To Treat Solid Tumor Cancers
HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today that the Center for Drug Evaluation of China’s National Medical Products Administration has granted clearance of the company’s Investigational New Drug (IND) application to begin a clinical trial of HF50 in patients with advanced solid tumor cancers.
Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers
HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today its CEO and Scientific Founder Yuhong Xu, Ph.D, presented positive safety and efficacy findings from an ongoing Phase 1 clinical trial of HF1K16 (K16) in refractory metastatic cancer patients at the European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain, September 13 – 17, 2024.
HighField Biopharmaceuticals Files IND in China for Clinical Trial of HF50, a Unique Lipid-Based T Cell Engager, to Treat Solid Tumor Cancers
HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today it has filed an investigational new drug (IND) application with China’s National Medical Products Administration to conduct a clinical trial of HF50, a first-of-its-kind immunoliposome that directs T cells to attack solid tumors and enhances the anticancer activity with an immune modulator.
HighField Biopharmaceuticals’ mRNA-based HFG1 Demonstrates Potential as a Longer Acting GLP-1R Agonist for Diabetic Control and Weight Loss
HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, said today naturally occurred diabetic monkeys experienced weight loss and HbA1c level reduction during an assessment period of two months following a single injection with HFG1. The data were presented at the American Diabetes Association (ADA) 84th Scientific Sessions June 21-24, 2024, in Orlando, FL.
HighField Biopharmaceuticals ASCO 2024 Poster Presentation Shows HFK1, a Unique Immunoliposome May Improve Clinical Outcomes over Antibody Drug Conjugates
HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, will present positive clinical and preclinical data of HFK1, a drug encapsulated immunoliposome for treatment of solid tumors, at the American Society of Clinical Oncology annual meeting May 31 – June 4, in Chicago, IL.
HighField Biopharmaceuticals to Present Preclinical Data of HFG1, a Unique mRNA-based GLP-1R Agonist, for Treatment of Diabetes, at ADA’s 84th Scientific Sessions
HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat cancer, diabetes and other diseases, announced today that its abstract of preclinical data evaluating an mRNA-based GLP-1R agonist (HFG1) in diabetic monkeys has been accepted for a poster presentation at the American Diabetes Association (ADA) 84th Scientific Sessions June 21-24, 2024, in Orlando, FL. The abstract also will be published on the website of the ADA’s journal Diabetes.
HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting
HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting May 31-June 4, 2024, in Chicago, IL.
HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors
HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today it has completed its Phase 1a study of HF1K16. Treating patients having multiple tumor types, the data demonstrated that the drug, administered as a single agent, is well-tolerated with only one dose-limiting toxicity (DLT) at the highest dose level. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid.
HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers
HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today the dosing of its first patient in its Phase 1 clinical trial of HFK1, a drug encapsulated immunoliposome containing doxorubicin for treatment of solid tumors.
HighField Biopharmaceuticals Announces Positive Phase 1a Data of HF1K16, a new Immuno-Oncology Drug, For Patients with Recurrent and Refractory Glioma
HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced results of its Phase 1a study of HF1K16 showing three of five patients with recurrent and refractory glioma had maintained disease control for more than 8 months with one patient experiencing complete response. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid.
HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma
HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the first patient has been dosed in a Phase 1b/2 trial of HF1K16 for recurrent and refractory glioma. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid (ATRA).
HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers
HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the U.S. Food and Drug Administration has granted clearance of the company’s Investigational New Drug (IND) application for HF158K1, a drug encapsulated immunoliposome containing doxorubicin.
HighField Biopharmaceuticals’ HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma
HighField Biopharmaceuticals (HighField Bio), a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced today the publication of an abstract including preliminary data from a Phase 1a clinical trial of HF1K16 in refractory metastatic cancer patients. It was published online at the American Society of Clinical Oncology (ASCO) Annual Meeting. HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid. The ASCO meeting is June 2 – 6, 2023, at the McCormick Place, Chicago, IL.
